Lauro et al [38] in 2014 evaluated the activity of cyproterone acetate (antiandrogen) as a monotherapy or in combination with Gonadotropin releasing hormone (GnRH) analogue in metastatic male breast cancer patients. Here, GNRH1 is linked to breast carcinoma.